Open AccessMesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort
Author(s) -
Gareth Rivalland,
Paul Mitchell,
Carmel Murone,
Khashayar Asadi,
Adrienne Morey,
Maud H.W. Starmans,
Paul C. Boutros,
Marzena Walkiewicz,
Benjamin Solomon,
Gavin Wright,
Simon Knight,
Thomas John
Publication year - 2019
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2019.03.11
Subject(s) - tissue microarray , kras , immunohistochemistry , polysomy , pathology , lung cancer , medicine , cancer research , mesenchyme , stage (stratigraphy) , microbiology and biotechnology , gene expression , cancer , biology , oncology , gene , colorectal cancer , epithelium , genetics , in situ hybridization , paleontology
In non-small cell lung cancer (NSCLC), mesenchyme to epithelial transition (MET) protein abundance increases with disease stage and is implicated in resistance to tyrosine kinase inhibitors. To better clarify the impact of MET overexpression on tumor behavior, we investigated a large cohort of patients who underwent curative surgical resection to determine whether MET gene amplification or protein abundance was prognostic.